Mutations in the FBN1 gene cause Marfan syndrome (MFS) and a wide range of overlapping phenotypes. The severe end of the spectrum is represented by neonatal MFS, the vast majority of probands carrying a mutation within exons 24-32. We previously showed that a mutation in exons 24-32 is predictive of a severe cardiovascular phenotype even in non-neonatal cases, and that mutations leading to premature truncation codons are under-represented in this region. To describe patients carrying a mutation in this so-called 'neonatal' region, we studied the clinical and molecular characteristics of 198 probands with a mutation in exons 24-32 from a series of 1013 probands with a FBN1 mutation (20%). When comparing patients with mutations leading to a premature termination codon (PTC) within exons 24-32 to patients with an in-frame mutation within the same region, a significantly higher probability of developing ectopia lentis and mitral insufficiency were found in the second group. Patients with a PTC within exons 24-32 rarely displayed a neonatal or severe MFS presentation. We also found a higher probability of neonatal presentations associated with exon 25 mutations, as well as a higher probability of cardiovascular manifestations. A high phenotypic heterogeneity could be described for recurrent mutations, ranging from neonatal to classical MFS phenotype. In conclusion, even if the exons 24-32 location appears as a major cause of the severity of the phenotype in patients with a mutation in this region, other factors such as the type of mutation or modifier genes might also be relevant.
Mutations in the FBN1 gene cause Marfan syndrome (MFS) and a wide range of overlapping phenotypes. The severe end of the spectrum is represented by neonatal MFS, the vast majority of probands carrying a mutation within exons 24-32. We previously showed that a mutation in exons 24-32 is predictive of a severe cardiovascular phenotype even in non-neonatal cases, and that mutations leading to premature truncation codons are under-represented in this region. To describe patients carrying a mutation in this so-called 'neonatal' region, we studied the clinical and molecular characteristics of 198 probands with a mutation in exons 24-32 from a series of 1013 probands with a FBN1 mutation (20%). When comparing patients with mutations leading to a premature termination codon (PTC) within exons 24-32 to patients with an in-frame mutation within the same region, a significantly higher probability of developing ectopia lentis and mitral insufficiency were found in the second group. Patients with a PTC within exons 24-32 rarely displayed a neonatal or severe MFS presentation. We also found a higher probability of neonatal presentations associated with exon 25 mutations, as well as a higher probability of cardiovascular manifestations. A high phenotypic heterogeneity could be described for recurrent mutations, ranging Introduction Marfan syndrome (MFS; MIM 154700) is a connective tissue disorder, with autosomal dominant inheritance and a prevalence of 1 in 5000 -10 000 individuals. 1 The cardinal features of MFS involve the ocular, cardiovascular and skeletal systems. 2 Neonatal MFS is considered as the severe end of the MFS phenotype, and most cases are sporadic.
Rare homozygote forms and a few compound heterozygote patients born to parents each displaying or not displaying a MFS phenotype, have been reported. 3, 4 Although the known mutations of FBN1 are spread over the entire gene, the mutations causing neonatal MFS seem to cluster in a specific region from exons 24 -32. 5 -7 Besides neonatal MFS, atypically severe phenotypes also cluster in exons 24 -32. 8 This region includes the central longest stretch of 12 cbEGF repeats, which is thought to form a rigid rod-like structure that may be important for microfibril assembly. Earlier, we showed that mutations in exons 24 -32 were associated with a more severe phenotype than mutations located in other exons of the gene, including younger age at diagnosis of type I fibrillinopathy, higher probability of ectopia lentis, ascending aortic dilatation, aortic surgery, mitral valve abnormalities, scoliosis and shorter survival. 9 The majority of these results was replicated even when neonatal cases were excluded, leading to the conclusion that exon 24 -32 mutations define a high-risk group for cardiac manifestations, associated with severe prognosis at all ages. 9 We also
showed an under-representation of nonsense mutations and an over-representation of missense mutations in this region, when compared with other exons of the gene. Here, we focus on the clinical and molecular characterization of patients with a mutation in the so-called exons 24 -32 'neonatal region', out of a series of 1013 probands with MFS or type I fibrillinopathy carrying a pathogenic FBN1 mutation.
Patients, materials and methods
Out of a series of 1013 probands carrying a pathogenic FBN1 mutation recruited for a genotype -phenotype correlation study, 13 The ages at diagnosis and at surgery for aortic dilatation, mitral valve prolapse and regurgitation, ectopia lentis and scoliosis were also collected. Patients were classified as 'neonatal MFS' when presenting with characteristic features of MFS including severe valvular anomalies by 4 weeks of age; 'severe MFS' when presenting with positive Ghent criteria including the presence of ascending aortic dilatation before 10 years of age; 'classical MFS' when Ghent criteria were positive in the remaining patients; 'incomplete MFS' when Ghent criteria were negative in adulthood and 'probable MFS' when Ghent criteria were negative and follow-up was limited to childhood. The pathogenic nature of a putative mutation was assessed using recognized criteria. In brief, all nonsense mutations, all deletions or insertions (in or out of frame) were considered pathogenic; for all splice mutations the wild-type and mutant strength values of the splice sites were compared using genetic algorithms 12, 14, 15 and only mutations displaying significant deviation from the normal were included. Missense mutations were considered pathogenic when at least one of the following features was found: (i) de novo missense mutation, (ii) missense mutation substituting or creating a cysteine, (iii) missense mutation involving a consensus calciumbinding residue, 16 (iv) substitution of glycines implicated in correct domain -domain packing, 17 (v) intrafamilial segregation of a missense mutation involving a conserved amino acid. For other missense mutations not displaying one of the above features, additional data provided by SIFT, 18, 19 BLOSUM-62 20 and biochemical value (http://cmgm.stanford.edu/biochem218/Projects%202001/ Yu.pdf) were gathered and analyzed using a new UMD tool 21 (G Collod-Beroud, personal communication).
The phenotypes and the genotypes of the overall cohort of patients are described elsewhere. 9, 10 Here, we focus on the clinical and molecular characteristics of patients with a mutation in exons 24 -32. We took advantage of this large series to study the MFS presentation types associated with these mutations, the distribution of mutations in this region and the genotype -phenotype correlations.
As the prevalence of many features of MFS increases with age, and as our study included patients with different lengths of follow-up, we performed a time-to-event analysis technique to estimate a reliable cumulative probability of observation of the different manifestations of MFS. This technique could be applied for the following events: diagnosis of MFS or type I fibrillinopathy, scoliosis, ectopia lentis, aortic dilatation or dissection, mitral abnormalities, as well as surgery for these different manifestations for which the age at diagnosis was systematically collected. In all time-to-event analyses, the baseline date (time zero) was the date of birth. The time-toevent diagnosis was defined as the interval between the baseline date and the date of event observation. Patients who did not manifest the studied event during the followup course were censored at their last follow-up. Patients for whom the age at diagnosis of a specific manifestation was not available were excluded from these analyses. The Kaplan -Meier method 22 was used to estimate the cumulative probabilities of clinical manifestations of the disease at 10, 25 and 40 years of age to describe the evolution of clinical features over time. Differences among the different types of mutation groups (different locations or type of mutations) were tested using the non-parametric log-rank test. For the other features (skeletal features other than scoliosis, skin, lung and dural involvement), for which the ages at diagnosis were not collected, age at last follow-up was the only information available concerning the time of clinical features observation. To indirectly take into account the length of patient follow-up even in this situation, we adjusted all comparisons of MFS manifestation proportions for the ages at last follow-up, categorized into 10-year age groups. These adjusted comparisons were performed using the Mantel -Haenszel test. 23 We compared the phenotypic data for each exon of the region with the others. To study the effect of mutation types, we compared patients with a premature termination codon (PTC) to patients with an in-frame mutation and patients with missense mutations involving a cysteine versus other missense mutations. We also searched if the position of the substituted cystein influenced the phenotype by comparing clinical data of patient with a mutation affecting the first disulfide bond with patients with a mutation in the second or third disulfide bond and conversely. To study the effect of the position of the affected EGF-like domain relative to the TGFBP-like domain, we compared the phenotype of patients with a missense mutation in exons 25 and 26 encoding EGF-like domains 11 and 12 (located near the TGFBP-like domain) to the phenotype of patients with a missense mutation in exons 27 -32 encoding EGFlike domains 13 -18. SASt software version 9.2 (SAS Institute Inc., Cary, NC, USA) and Stata software version 9 (Stata Corp, College Station, TX, USA) were used for all statistical analyses. To take into account multiple testing, only P-values of less than 0.001 were considered significant.
Results
The genotype -phenotype correlation study in exons 24 -32 versus other exons has been reported elsewhere. 9 The MFS presentation type of patients with a mutation in exons 24 -32 is summarized in Figure 1 . An over-representation of neonatal and severe MFS and an under-representation of classical MFS were noted when compared to the overall series. 9 Accordingly, a high percentage of sporadic cases were found (69%). Twenty percent of the FBN1 mutations in the overall series were found in the exons 24 -32 region (n ¼ 198), indicating a clustering of mutations in this region as only 14.5% was expected based on the length of genomic sequence of the gene. Figure 2 shows the number of mutations by exon, from exons 24 to 32, and, although results were nonsignificant, the clustering of mutations can be mainly explained by an excess of mutations in exons 25 and 27. An unequal distribution regarding the type of MFS presentation was found between exons of the studied region, with severe phenotypes most likely to be associated with mutations in exons 25, 26, 29, 31 and 32. Conversely, neonatal MFS was under-represented in patients with a mutation in exons 24, 27, 28 and 30 (Table 1) . When comparing the probability of the different clinical features for one individual exon compared to the other exons of the region, significant results were found only for patients carrying a mutation in exon 25. Indeed, a younger age at diagnosis of MFS or type I fibrillinopathy, a higher probability of ascending aortic dilatation, mitral regurgitation, valvular surgery and scoliosis, as well as a lower chance of survival were all found when compared to patients with a mutation within other exons of the exons 24 -32 region (Figure 3 ). These results can be explained at least in part by a higher frequency of patients with neonatal MFS in exon 25 (57%, Table 1, Po0.001). The majority of mutations was in-frame and predicted to result in an altered protein (79%), while 21% were predicted to result in a PTC. Within the 139 missense mutations, 75 involved a cysteine (54%). Twenty-five mutations affected the first disulfide bond, 11 mutations the second disulfide bond and 23 mutations the third disulfide bond. Fifty-two patients had a mutation in the EGF-like domains 11 or 12, and 96 in the EGF-like domains 13 -17. Figure 4 presents the distribution of types of mutations, depending on the severity of the clinical presentation. In particular, PTCs were under-represented in patients with severe phenotypes and an absence of nonsense mutations, while missense mutations were over-represented. We questioned whether the type of mutation within the exons 24 -32 region could lead to a differing clinical phenotype. Some significant results were found when patients with an exons 24 -32 PTC mutation were compared with patients with an exons 24 -32 missense mutation ( Figure 5) . Indeed, the cumulative probability of mitral insufficiency diagnosed before or at 25 years was 54% (99.9% CI ¼ 39 -69%) in patients with a missense mutation in exons 24 -32, compared to 20% (99.9% CI ¼ 5 -53%) in patients with a PTC mutation in the same region (log-rank test P ¼ 0.001). Similarly, the cumulative probability of ectopia lentis diagnosed before or at 25 years was 61% (99.9% CI ¼ 45 -77%) in patients with a missense mutation in exons 24 -32, compared to 31% (99.9% CI ¼ 11 -63%) in patients with a PTC mutation in the same region (log-rank test P ¼ 0.0009). Conversely, a higher frequency of pectus deformity was found in patients with a PTC mutation in exons 24 -32 when compared to patients with a missense mutation in the same region (83 versus 54%, MH test P ¼ 0.001). No significant results were found for the other clinical features of the MFS spectrum. A tendency towards a higher probability of ascending aortic dilatation and a younger age at diagnosis was noted with missense mutations, although these associations were only marginally significant (P ¼ 0.0218 and 0.0278, respectively) ( Figure 5 ). When comparing patients with missense mutations involving a cysteine to other missense mutations, significant results were found for ectopia lentis. Indeed, the cumulative probability of ectopia lentis CI ¼ 25 -63%) in patients with another missense mutation in the same region (log-rank test P ¼ 0.0001). A tendency towards a higher probability of ascending aortic dilatation was noted in patients with missense mutations involving a cysteine, although this association was only marginally significant (P ¼ 0.0022) ( Figure 5 ). No significant differences were found when comparing clinical data of patients with a mutation affecting the first, second or third disulfide bond but the numbers were small. Significant differences were found when comparing the clinical phenotype of patients carrying a missense mutation in exons 25 and 26 encoding EGF-like domains 11 and 12 located near the TGFBP-like domain with patients carrying a missense mutation in exons 27 -32 encoding EGF-like domains 13 -18. Indeed, patients with a missense mutation affect- ing EGF-like domains 11 or 12 (n ¼ 52) have a shorter survival, a younger age at diagnosis, a higher risk of presenting a neonatal presentation, a higher risk of developing ascending aortic dilatation and a higher risk of developing mitral insufficiency than patients with a missense mutation affecting EGF-like domains 13 -17 (Po0.001). Twenty-four mutations were recurrent. Table 2 shows the MFS presentation types in these recurrent mutations. Interestingly, some recurrent mutations lead to a similar phenotype, while others lead to different presentations.
Discussion
Here, we further delineate the clinical and molecular characteristics of the so-called 'neonatal exons 24 -32 region' from the data of a large series in which the phenotype of 1013 probands with MFS and other type I fibrillinopathies were collected. We confirm that the region encompassing exons 24 to 32 is associated with more severe phenotypes than the other exons of the gene.
Indeed, one-third of the patients with a mutation within this region had neonatal or severe MFS, as compared to 6% in the other regions. 9 We showed previously that the presence of a mutation in exons 24 -32 was predictive of a severe cardiovascular phenotype even in non-neonatal phenotypes, 9 but it is unknown if the location of the mutation is the only cause of the phenotypic severity. Genotype -phenotype correlation analyses can be complicated by the fact that both the location and the type of a mutation are critical in producing a severe phenotype and these data are often studied independently. For this reason, we looked for clinical differences between patients with different mutation types within this region. A higher probability of mitral regurgitation and ectopia lentis, as well as a lower frequency of pectus deformity were found in patients with a missense mutation within this region when compared to patients with a PTC mutation. Also, a higher probability of ectopia lentis was found in patients with a missense mutation involving a cysteine within this region when compared to patients with other missense mutations. The cumulative probability of ascending aortic dilatation before or at 25 years was 74% (99.9% CI ¼ 60 -86%) in patients with a missense mutation in exons 24 -32 (solid line) compared to 40% (99.9% CI ¼ 18 -70%) in patients with a PTC mutation in the same region (broken line), but these results were not significant because the curves join together with follow-up (P ¼ 0.0218). (c) Probability of ectopia lentis in missense mutations in exons 24 -32 versus PTC mutations in the same region. The cumulative probability of ectopia lentis diagnosed before or at 25 years was 61% (99.9% CI ¼ 45 -77%) in patients with a missense mutation in exons 24 -32 (solid line) compared to 31% (99.9% CI ¼ 11 -63%) in patients with a PTC mutation in the same region (broken line) (P ¼ 0.0009). (d) Age at diagnosis of type I fibrillinopathy in missense mutations in exons 24 -32 versus PTC mutations in the same region. Fifty-five percent of patients with a missense mutation in exons 24 -32 (solid line) were diagnosed at 6 years (IQR (0.7;18)) of age versus 21 years (IQR (11;32)) of age in patients with a PTC mutation in the same region (broken line), but results of the log-rank test were not significant because the curves join together with follow-up (P ¼ 0.0278). (e) Probability of ascending aortic dilatation in missense mutations involving a cysteine in exons 24 -32 versus other missense mutations in the same region. The cumulative probability of ascending aortic dilatation before or at 25 years was 83% (99.9% CI ¼ 70 -92%) in patients with a missense mutation involving a cysteine in exons 24 -32 (solid line) compared to 62% (99.9% CI ¼ 45 -78%) in patients with another missense mutation in the same region (broken line), but these results were only marginally significant (P ¼ 0.0022). (f) Probability of ectopia lentis in missense mutations involving a cysteine in exons 24 -32 versus other missense mutations in the same region. The cumulative probability of ectopia lentis diagnosed before or at 25 years was 76% (99.9% CI ¼ 60 -89%) in patients with a missense mutation involving a cysteine in exons 24 -32 (solid line) compared to 41% (99.9% CI ¼ 25 -63%) in patients with another missense mutation in the same region (broken line) (P ¼ 0.0001).
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These results were highly superposable to those obtained for all the regions of the FBN1 gene, 9 showing that, beside the predominant role of the location of the mutations within the exons 24 -32 region, the type of mutation is also important. We showed previously that the distribution of the mutation types in exons 24 -32 is different from the distribution found in other exons of the gene. Indeed, mutations leading to PTC are under-represented, contrasting with an over-representation of in-frame mutations. 9 Here, we show that PTC mutations are under-represented in the severe MFS phenotype. In particular, nonsense mutations have never been described in association with neonatal and severe MFS presentations. In contrast, in the overall cohort, we showed that patients with an FBN1 PTC mutation had a more severe skeletal and skin phenotype than patients with an in-frame mutation. 9 Therefore, it is not known whether the absence of nonsense mutations in the neonatal and severe phenotypes, as well as the under-representation of PTC mutations in these phenotypes, could be explained by early lethality or by a milder effect on phenotype of PTC mutations within this region.
In searching for differences in various clinical system involvements between PTC and in-frame mutations within this region, there were no emerging clues for this region regarding the dominant negative versus haploinsufficiency pathogenesis models and no evidence to support a differential mechanism for the phenotypic and genotypic differences within the exons 24 -32 region and other regions of the gene. Recent data have highlighted the complexity of the pathogenicity of FBN1 mutations, with some mutations acting as dominant negative, and others as haploinsufficiency secondary to different effects on trafficking. 44 -47 However, mutation data accumulated by diagnostic laboratories worldwide are generally not associated with mRNA and protein studies. Therefore, no data are available to assess the true effect of PTC mutations and whether they are submitted to nonsense-mediated LTBP plays a role in the assembly and secretion of TGFb1 and is thought to target TGFb1 to particular extracellular matrix sites, thus controlling the production and structure of the extracellular matrix, along with affecting cell growth, morphology and differentiation. 52, 53 The homology of fibrillin-1 and LTBP raises the possibility that disruption of the extracellular targeting of the action of TGFb1 during development underpins the more severe phenotype. Alternatively, mutations in this region of fibrillin-1 may be more disruptive to microfibril formation. Although mutations throughout the FBN1 gene have been shown to disrupt fibrillin-1 incorporation into microfibrils, exons 24 -32 may encode a region of fibrillin-1 with a unique function in the multimerization of the protein into stable microfibrils. In contrast to microfibrils formed by classic MFS fibroblasts, the fibrils formed by neonatal MFS show not only an apparent decrease in fibrillin accumulation, but are also short, fragmented and frayed. 24 Therefore, alterations in this region of the protein may have a significant and specific effect on microfibril formation, implying a unique role of this region in microfibril formation.
Finally, the study of recurrent mutations was of interest. The majority of these recurrent mutations were only found in two instances. Three mutations were represented in five instances or more. Although the c.3302A4G mutation was generally associated with the classical MFS, the c.3037G4A mutation led to different phenotypes, ranging from neonatal to classical MFS. Five mutations responsible for a neonatal MFS phenotype in some patients were also found in other patients with another MFS type of presentation (c.3037G4A, c.3143T4C, c.3202T4C, c.3217G4A and c.3976T4C). These data give further emphasis to the clinical variability in FBN1 mutations and strongly argue for the role of modifier genes or the existence of a digenic mechanism to explain neonatal MFS.
In conclusion, even if the exons 24 -32 location of mutations appears as a major cause of the severity of the phenotype in patients harboring a mutation in this region, other factors such as the type of mutation or modifier genes might also be involved. These data could be helpful in understanding the role of the central region of the FBN1 gene in disease pathogenicity.
